Padagis has announced a $36 million expansion of its manufacturing facilities in Minneapolis, MN, USA, specifically highlighting the new capacity to manufacture naloxone nasal spray in the US. According to the company, “The additional capabilities will ensure faster delivery and greater access to Padagis’ nasal sprays and specifically Padagis’ naloxone.” The company says that it will start producing naloxone nasal spray at the Minneapolis plant by the end of this year.
Former Padagis parent company Perrigo filed an ANDA for a generic of Narcan naloxone nasal spray in 2018. The FDA issued a temporary approval for the ANDA in 2020 and final approval in 2022. Padagis launched the nasal spray in the US in June 2022. and the FDA approved a switch to over-the-counter (OTC) sales in July 2023.
Padagis President Pamela Hoffman commented, “This is more than an investment, it’s a commitment to saving lives. By bringing naloxone production to the US, we can respond faster in times of urgent need and ensure this critical medication is always within reach for the communities who need it most.”
Read the Padagis press release
